Dana Farber | Strategic Alliance Partners

Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.

Latest from Dana Farber

New Strategies Enhance Care in mUC

November 25, 2020

November 25, 2020 — Although metastatic urothelial carcinoma remains generally incurable, management of bladder cancer has witnessed several multidisciplinary advances in the past few years.

Next-Generation Endocrine Therapy Moves Forward in Breast Cancer Trial

November 23, 2020

November 24, 2020 — Amcenestrant, a new oral form of endocrine therapy that has shown early signs of efficacy, is being evaluated against the current standards of care in patients with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer.

Adagrasib Shows Early Efficacy in KRAS G12C-Mutant NSCLC and CRC

November 11, 2020

Adagrasib, a novel agent aimed at KRAS G12C mutations, has demonstrated early signs of efficacy in patients with advanced non–small cell lung cancer and colorectal cancer whose tumors harbor the alteration, raising hopes for a new therapy against a challenging oncogenic target.

Stamford Hospital and Dana-Farber/Brigham and Women’s Cancer Center Announce Expanded Collaboration

November 10, 2020

Dana-Farber/Brigham and Women’s Cancer Center​​​ ​formally announced an exclusive, expanded collaboration to increase access to DF/BWCC experts and resources for patients at Stamford Health’s Carl & Dorothy Bennett Cancer Center.